- Home
- ZENA vs MRSN Comparison
ZENA vs MRSN Comparison
Compare ZENA & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENA
- MRSN
- Stock Information
- Founded
- ZENA 2017
- MRSN 2001
- Country
- ZENA Canada
- MRSN United States
- Employees
- ZENA N/A
- MRSN N/A
- Industry
- ZENA
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ZENA
- MRSN Health Care
- Exchange
- ZENA NYSE
- MRSN Nasdaq
- Market Cap
- ZENA 82.4M
- MRSN 71.9M
- IPO Year
- ZENA N/A
- MRSN 2017
- Fundamental
- Price
- ZENA $2.62
- MRSN $0.34
- Analyst Decision
- ZENA
- MRSN Buy
- Analyst Count
- ZENA 0
- MRSN 3
- Target Price
- ZENA N/A
- MRSN $4.00
- AVG Volume (30 Days)
- ZENA 610.6K
- MRSN 3.0M
- Earning Date
- ZENA 01-01-0001
- MRSN 03-03-2025
- Dividend Yield
- ZENA N/A
- MRSN N/A
- EPS Growth
- ZENA N/A
- MRSN N/A
- EPS
- ZENA N/A
- MRSN N/A
- Revenue
- ZENA $1,364,714.00
- MRSN $40,497,000.00
- Revenue This Year
- ZENA N/A
- MRSN N/A
- Revenue Next Year
- ZENA N/A
- MRSN N/A
- P/E Ratio
- ZENA N/A
- MRSN N/A
- Revenue Growth
- ZENA 7.43
- MRSN 9.88
- 52 Week Low
- ZENA $1.41
- MRSN $0.32
- 52 Week High
- ZENA $12.43
- MRSN $4.64
- Technical
- Relative Strength Index (RSI)
- ZENA N/A
- MRSN 29.53
- Support Level
- ZENA N/A
- MRSN $0.41
- Resistance Level
- ZENA N/A
- MRSN $0.42
- Average True Range (ATR)
- ZENA 0.00
- MRSN 0.04
- MACD
- ZENA 0.00
- MRSN -0.00
- Stochastic Oscillator
- ZENA 0.00
- MRSN 11.85
About ZENA ZENATECH INC
ZenaTech Inc is a enterprise software technology company that specializes in mission-critical cloud-based applications integrated with smart hardware to deliver innovative solutions across diverse industries. The Company operates in software development technology, sales, and distribution. The Company is also developing a drone manufacturing, sales, and distribution business. The company operates in two segments which is software development technology, sales, and distribution, as well as drone manufacturing, sales, and distribution.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.